Compugen Ltd. (CGEN) 股票分析

公司概述

Compugen Ltd. operates as a clinical-stage therapeutic discovery and development company focused on the research, development, and commercialization of therapeutics and product candidates across Israel, the United States, and Europe. The company functions within the Healthcare sector, specifically the Biotechnology industry, which implies a business model reliant on high-risk, high-reward innovation in drug discovery rather than traditional manufacturing or service provision. As of the latest data, the enterprise possesses a market capitalization of $235.53M and generates annual revenue of $72.76M with an operational workforce of 75 employees. These valuation and revenue figures indicate that Compugen Ltd. maintains a relatively small market footprint compared to large-cap pharmaceutical giants, positioning it as a mid-cap entity with significant growth potential but limited current revenue scale. The modest employee count relative to its revenue suggests a highly capitalized, asset-light operational model typical of biotechnology firms that leverage external partnerships or proprietary technology platforms to drive efficiency.

财务健康

The company reported a trailing twelve-month revenue of $72.76M and a net income of $35.34M, resulting in an EBITDA of $31.80M. The substantial gap between the reported revenue of $72.76M and the net income of $35.34M reveals an exceptionally lean cost structure where operating expenses are minimal relative to top-line generation. Compugen Ltd. demonstrates robust financial flexibility with free cash flow of $24.33M, indicating that the business generates sufficient cash from operations to cover capital expenditures and debt obligations without relying on external financing. The company's margin profile is highly efficient, boasting a gross margin of 87.3%, an operating margin of 83.2%, and a profit margin of 48.6%, which collectively signal strong pricing power or low variable costs typical of software-driven or platform-based biotechnology models. Liquidity and solvency are supported by a cash balance of $145.64M against a negligible debt level of $2.96M, while the debt-to-equity ratio stands at 2.88. Despite the elevated debt-to-equity figure, the balance sheet is effectively conservative given the massive cash cushion relative to liabilities. Short-term liquidity is further evidenced by a current ratio of 6.56, which indicates a substantial buffer of current assets to cover current liabilities well beyond standard safety thresholds. Return on Equity is recorded at 44.8% and Return on Assets is 14.4%, metrics that reveal highly effective management in generating returns on the capital employed, particularly given the low absolute debt exposure.

估值评估

The valuation metrics present a distinct divergence between historical performance and forward expectations, with a trailing P/E ratio of 6.53 and a forward P/E of -7.44. This negative forward P/E implies that analysts or the market expects earnings to contract or turn negative in the upcoming period, despite the strong historical profitability shown by the trailing twelve-month figures. The price-to-book ratio is 2.28, suggesting that the market prices the company at a significant premium over its net asset value, reflecting the high value placed on its intellectual property and platform technology. Alternative valuation multiples such as a price-to-sales ratio of 3.24 and an EV/EBITDA of 2.89 suggest that the stock is priced based on revenue generation and cash flow efficiency rather than current earnings multiples. The stock's trading range over the past year spans from a 52-week low of $1.13 to a high of $2.49, providing context for price volatility relative to recent historical performance. The beta value of 2.77 indicates that the stock exhibits high price volatility, moving with approximately 2.77 times the magnitude of the broader market, which aligns with the typical risk profile of small-cap biotechnology stocks.

Growth & Income

Revenue growth year-over-year is reported at an extraordinary 4477.3%, while earnings growth is listed as N/A. The absence of a specific earnings growth figure alongside such massive revenue expansion suggests that the recent revenue surge may be driven by one-time events, accounting adjustments, or a specific segment inclusion rather than sustained operational scaling. Since the company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, it follows a growth-oriented strategy where earnings are retained and reinvested into research and development pipelines. The company's overall growth and income profile is characterized by explosive top-line expansion and zero capital distribution to shareholders, prioritizing capital allocation toward expanding its therapeutic discovery capabilities. This reinvestment approach is consistent with clinical-stage biotechnology companies that seek to maximize long-term value through pipeline development rather than immediate shareholder yield.